1
|
Asam K, Lewis KA, Kober K, Gong X, Kanaya AM, Aouizerat BE, Flowers E. Multi-Tiered Assessment of Gene Expression Provides Evidence for Mechanisms That Underlie Risk for Type 2 Diabetes. Diabetes Metab Syndr Obes 2023; 16:3445-3457. [PMID: 37929060 PMCID: PMC10625391 DOI: 10.2147/dmso.s428572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Accepted: 10/25/2023] [Indexed: 11/07/2023] Open
Abstract
Introduction Integrated transcriptome and microRNA differential gene expression (DEG) analyses may help to explain type 2 diabetes (T2D) pathogenesis in at-risk populations. The purpose of this study was to characterize DEG in banked biospecimens from underactive adult participants who responded to a randomized clinical trial measuring the effects of lifestyle interventions on T2D risk factors. DEGs were further examined within the context of annotated biological pathways. Methods Participants (n = 52) in a previously completed clinical trial that assessed a 12-week behavioural intervention for T2D risk reduction were included. Participants who showed >6mg/dL decrease in fasting blood glucose were identified as responders. Gene expression was measured by RNASeq, and overrepresentation analysis within KEGG pathways and weighted gene correlation network analysis (WGCNA) were performed. Results No genes remained significantly differentially expressed after correction for multiple comparisons. One module derived by WGCNA related to body mass index was identified, which contained genes located in KEGG pathways related to known mechanisms underlying risk for T2D as well as pathways related to neurodegeneration and protein misfolding. A network analysis showed indirect connections between genes in this module and islet amyloid polypeptide (IAPP), which has previously been hypothesized as a mechanism for T2D. Discussion We validated prior studies that showed pathways related to metabolism, inflammation/immunity, and endocrine/hormone function are related to risk for T2D. We identified evidence for new potential mechanisms that include protein misfolding. Additional studies are needed to determine whether these are potential therapeutic targets to decrease risk for T2D.
Collapse
Affiliation(s)
- Kesava Asam
- Bluestone Center for Clinical Research, New York University, New York City, NY, USA
| | - Kimberly A Lewis
- Department of Physiological Nursing, University of California, San Francisco, CA, USA
| | - Kord Kober
- Department of Physiological Nursing, University of California, San Francisco, CA, USA
- Bakar Computational Health Sciences Institute, University of California, San Francisco, CA, USA
| | - Xingyue Gong
- Department of Physiological Nursing, University of California, San Francisco, CA, USA
| | - Alka M Kanaya
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
- Department of Medicine, University of California, San Francisco, CA, USA
| | - Bradley E Aouizerat
- Bluestone Center for Clinical Research, New York University, New York City, NY, USA
- Department of Oral and Maxillofacial Surgery, New York University, New York City, NY, USA
| | - Elena Flowers
- Department of Physiological Nursing, University of California, San Francisco, CA, USA
- Institute for Human Genetics, University of California, San Francisco, CA, USA
| |
Collapse
|
2
|
Kariuki D, Aouizerat BE, Asam K, Kanaya AM, Zhang L, Florez JC, Flowers E. MicroRNA biomarkers target genes and pathways associated with type 2 diabetes. Diabetes Res Clin Pract 2023; 203:110868. [PMID: 37543292 DOI: 10.1016/j.diabres.2023.110868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 07/25/2023] [Accepted: 08/03/2023] [Indexed: 08/07/2023]
Abstract
AIMS/HYPOTHESIS Our prior analysis of the Diabetes Prevention Program study identified a subset of five miRNAs that predict incident type 2 diabetes. The purpose of this study was to identify mRNAs and biological pathways targeted by these five miRNAs to elucidate potential mechanisms of risk and responses to the tested interventions. METHODS Using experimentally validated data from miRTarBase version 8.0 and R (2021), we identified mRNAs with strong evidence to be regulated by individual or combinations of the five predictor miRNAs. Overrepresentation of the mRNA targets was assessed in pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation database. RESULTS The five miRNAs targeted 167 pathways and 122 mRNAs. Nine of the pathways have known associations with type 2 diabetes: Insulin signaling, Insulin resistance, Diabetic cardiomyopathy, Type 2 diabetes, AGE-RAGE signaling in diabetic complications, HIF-1 signaling, TGF-beta signaling, PI3K/Akt signaling, and Adipocytokine signaling pathways. Vascular endothelial growth factor A (VEGFA) has prior genetic associations with risk for type 2 diabetes and was the most commonly targeted mRNA for this set of miRNAs. CONCLUSIONS/INTERPRETATION These findings show that miRNA predictors of incident type 2 diabetes target mRNAs and pathways known to underlie risk for type 2 diabetes. Future studies should evaluate miRNAs as potential therapeutic targets for preventing and treating type 2 diabetes.
Collapse
Affiliation(s)
- Dorian Kariuki
- University of California, San Francisco, Department of Physiological Nursing, San Francisco, CA, USA
| | - Bradley E Aouizerat
- New York University Bluestone Center for Clinical Research, New York, NY 10010, USA; New York University Department of Oral and Maxillofacial Surgery, New York, NY 10010, USA
| | - Kesava Asam
- New York University Bluestone Center for Clinical Research, New York, NY 10010, USA
| | - Alka M Kanaya
- University of California, San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA, USA; University of California, San Francisco, Department of Medicine, Division of Hematology and Oncology, San Francisco, CA, USA
| | - Li Zhang
- University of California, San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA, USA; University of California, San Francisco, Department of Medicine, Division of General Internal Medicine, San Francisco, CA, USA
| | - Jose C Florez
- Center for Genomic Medicine and Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Programs in Metabolism and Medical &Population Genetics, Broad Institute, Cambridge, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Elena Flowers
- University of California, San Francisco, Department of Physiological Nursing, San Francisco, CA, USA; University of California, San Francisco, Institute for Human Genetics, San Francisco, CA, USA.
| |
Collapse
|
3
|
Kariuki D, Asam K, Aouizerat BE, Lewis KA, Florez JC, Flowers E. Review of databases for experimentally validated human microRNA-mRNA interactions. Database (Oxford) 2023; 2023:7142843. [PMID: 37098414 PMCID: PMC10129384 DOI: 10.1093/database/baad014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 01/13/2023] [Accepted: 03/09/2023] [Indexed: 04/27/2023]
Abstract
MicroRNAs (miRs) may contribute to disease etiology by influencing gene expression. Numerous databases are available for miR target prediction and validation, but their functionality is varied, and outputs are not standardized. The purpose of this review is to identify and describe databases for cataloging validated miR targets. Using Tools4miRs and PubMed, we identified databases with experimentally validated targets, human data, and a focus on miR-messenger RNA (mRNA) interactions. Data were extracted about the number of times each database was cited, the number of miRs, the target genes, the interactions per database, experimental methodology and key features of each database. The search yielded 10 databases, which in order of most cited to least were: miRTarBase, starBase/The Encyclopedia of RNA Interactomes, DIANA-TarBase, miRWalk, miRecords, miRGator, miRSystem, miRGate, miRSel and targetHub. Findings from this review suggest that the information presented within miR target validation databases can be enhanced by adding features such as flexibility in performing queries in multiple ways, downloadable data, ongoing updates and integrating tools for further miR-mRNA target interaction analysis. This review is designed to aid researchers, especially those new to miR bioinformatics tools, in database selection and to offer considerations for future development and upkeep of validation tools. Database URL http://mirtarbase.cuhk.edu.cn/.
Collapse
Affiliation(s)
- Dorian Kariuki
- Department of Physiological Nursing, University of California, San Francisco, CA 94143, USA
| | - Kesava Asam
- Bluestone Center for Clinical Research, New York University, New York, CA 10010, USA
| | - Bradley E Aouizerat
- Bluestone Center for Clinical Research, New York University, New York, CA 10010, USA
- Department of Oral and Maxillofacial Surgery, New York University, New York, CA 10010, USA
| | - Kimberly A Lewis
- Department of Physiological Nursing, University of California, San Francisco, CA 94143, USA
| | - Jose C Florez
- Department of Medicine, Center for Genomic Medicine and Diabetes Unit, Massachusetts General Hospital, Boston, MA 02114, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute, Cambridge, MA 02142, USA
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Elena Flowers
- Department of Physiological Nursing, University of California, San Francisco, CA 94143, USA
- Institute for Human Genetics, University of California, San Francisco, CA 94143, USA
| |
Collapse
|
4
|
Aguiar T, Mashiko S, Roy P, Dietzel M, Asam K, Aouizerat B, Genkinger J, Remotti H, Zorn E. Abstract 601: Serological responses to tumor-associated adducts in pancreatic cancer. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
The incidence of pancreatic cancer has increased over the past several decades and is now the fourth leading cause of cancer death in the USA. Only 8.5% of the patients live beyond 5 years after their initial diagnosis. This dismal survival rate is partly explained by the fact that most pancreatic cancer cases are detected late when treatment options are limited. Novel biomarkers are crucially needed. It has long been recognized that cancer cells abnormally accumulate chemical groups covalently linked to proteins, DNA and other molecules. Humoral responses to these “adducts” have not been thoroughly explored. To investigate these responses, we developed an ELISA platform for the detection of serum IgG reactive to 93 adducts, including post-translational modifications known to contribute to tumorigenesis, progression, and metastasis. Our panel also includes oxidation-related modification, advanced glycation end products, and certain co-enzymes that qualify as adducts based on their binding properties. Using this assay, we measured anti-adduct antibodies in the serum of adult healthy donors (N=24; age range 40-80) as well as patients with pancreatic cancer (N=31; age range 50-90). Importantly, all patient specimens were collected before any treatment. Reactivity to all adducts was analyzed using a random forest predictive model with 10,000 bootstrapped decision trees to distinguish between the two groups. Results revealed a distinctive anti-adduct IgG reactivity profile for pancreatic cancer patients when compared to controls. Applying feature selection using the Boruta algorithm identified a reduced set of 19 target adducts recognized by IgG that most efficiently discriminated between healthy donors and pancreatic cancer cases. All 19 adducts were confirmed as IgG targets in cancer patients using multiple unpaired t-tests (p≤0,05). Aside from their predictive value, we reasoned that the detection of adduct-specific antibodies in cancer patients reflected their accumulation in the tumor cells. To test this hypothesis, we assessed the level of two representative target adducts by immunofluorescence staining in tumor tissue compared to control adjacent non-tumoral tissue or healthy tonsil. Results unequivocally show higher levels of these two adducts in cancer cells compared to non-cancer cells. Taken together, these preliminary findings support our hypothesis of the development of anti-adduct antibodies in pancreatic cancer patients. Furthermore, the specific antibody signature detected in these patients is consistent with the abnormal presence of corresponding adducts in the transformed cells. Our findings pave the way for the development of diagnostic tests based on the detection of serum IgG specific to tumor-associated adducts.
Citation Format: Talita Aguiar, Shunya Mashiko, Poulomi Roy, Max Dietzel, Kesava Asam, Bradley Aouizerat, Jeanine Genkinger, Helen Remotti, Emmanuel Zorn. Serological responses to tumor-associated adducts in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 601.
Collapse
Affiliation(s)
- Talita Aguiar
- 1Columbia University Irving Medical Center, New York, NY
| | - Shunya Mashiko
- 1Columbia University Irving Medical Center, New York, NY
| | - Poulomi Roy
- 1Columbia University Irving Medical Center, New York, NY
| | - Max Dietzel
- 1Columbia University Irving Medical Center, New York, NY
| | | | | | | | - Helen Remotti
- 1Columbia University Irving Medical Center, New York, NY
| | - Emmanuel Zorn
- 1Columbia University Irving Medical Center, New York, NY
| |
Collapse
|
5
|
Doan C, Aouizerat BE, Ye Y, Dang D, Asam K, Bhattacharya A, Howard T, Patel YK, Viet DT, Figueroa JD, Zhong JF, Thomas CM, Morlandt AB, Yu G, Callahan NF, Allen CT, Grandhi A, Herford AS, Walker PC, Nguyen K, Kidd SC, Lee SC, Inman JC, Slater JM, Viet CT. Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer. Adv Biol (Weinh) 2022; 6:e2200190. [PMID: 35925599 PMCID: PMC9533666 DOI: 10.1002/adbi.202200190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 07/14/2022] [Indexed: 01/28/2023]
Abstract
Oral squamous cell carcinoma (OSCC) patients suffer from poor survival due to metastasis or locoregional recurrence, processes that are both facilitated by perineural invasion (PNI). OSCC has higher rates of PNI than other cancer subtypes, with PNI present in 80% of tumors. Despite the impact of PNI on oral cancer prognosis and pain, little is known about the genes that drive PNI, which in turn drive pain, invasion, and metastasis. In this study, clinical data, preclinical, and in vitro models are leveraged to elucidate the role of neurotrophins in OSCC metastasis, PNI, and pain. The expression data in OSCC patients with metastasis, PNI, or pain demonstrate dysregulation of neurotrophin genes. TrkA and nerve growth factor receptor (NGFR) are focused, two receptors that are activated by NGF, a neurotrophin expressed at high levels in OSCC. It is demonstrated that targeted knockdown of these two receptors inhibits proliferation and invasion in an in vitro and preclinical model of OSCC, and metastasis, PNI, and pain. It is further determined that TrkA knockdown alone inhibits thermal hyperalgesia, whereas NGFR knockdown alone inhibits mechanical allodynia. Collectively the results highlight the ability of OSCC to co-opt different components of the neurotrophin pathway in metastasis, PNI, and pain.
Collapse
Affiliation(s)
- Coleen Doan
- Department of Oral & Maxillofacial Surgery, Loma Linda University School of Dentistry, Loma Linda, CA
| | - Bradley E. Aouizerat
- Department of Oral & Maxillofacial Surgery, New York University College of Dentistry, NY, United States
- Bluestone Center for Clinical Research, New York University College of Dentistry, NY, United States
| | - Yi Ye
- Department of Oral & Maxillofacial Surgery, New York University College of Dentistry, NY, United States
- Bluestone Center for Clinical Research, New York University College of Dentistry, NY, United States
| | - Dongmin Dang
- Department of Oral & Maxillofacial Surgery, New York University College of Dentistry, NY, United States
- Bluestone Center for Clinical Research, New York University College of Dentistry, NY, United States
| | - Kesava Asam
- Department of Oral & Maxillofacial Surgery, New York University College of Dentistry, NY, United States
- Bluestone Center for Clinical Research, New York University College of Dentistry, NY, United States
| | - Aditi Bhattacharya
- Department of Oral & Maxillofacial Surgery, New York University College of Dentistry, NY, United States
- Bluestone Center for Clinical Research, New York University College of Dentistry, NY, United States
| | - Timothy Howard
- Bluestone Center for Clinical Research, New York University College of Dentistry, NY, United States
| | - Yogin K. Patel
- Bluestone Center for Clinical Research, New York University College of Dentistry, NY, United States
| | - Dan T. Viet
- Bluestone Center for Clinical Research, New York University College of Dentistry, NY, United States
| | - Johnny D. Figueroa
- Department of Basic Sciences, Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, CA, United States
| | - Jiang F. Zhong
- Department of Basic Sciences, Loma Linda University, School of Medicine, Loma Linda, CA
| | - Carissa M. Thomas
- Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL
| | - Anthony B. Morlandt
- Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL
- Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL
| | - Gary Yu
- Rory Meyers College of Nursing, New York University, New York, NY
| | - Nicholas F. Callahan
- Department of Oral and Maxillofacial Surgery, University of Illinois Chicago, College of Dentistry, Chicago, IL
| | - Clint T. Allen
- Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH), Bethesda, MD
| | - Anupama Grandhi
- Department of Oral & Maxillofacial Surgery, Loma Linda University School of Dentistry, Loma Linda, CA
| | - Alan S. Herford
- Department of Oral & Maxillofacial Surgery, Loma Linda University School of Dentistry, Loma Linda, CA
| | - Paul C. Walker
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA
| | - Khanh Nguyen
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA
| | - Stephanie C. Kidd
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA
| | - Steve C. Lee
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA
| | - Jared C. Inman
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA
| | - Jason M. Slater
- Department of Radiation Medicine, Loma Linda University School of Medicine, Loma Linda, CA
| | - Chi T. Viet
- Department of Oral & Maxillofacial Surgery, Loma Linda University School of Dentistry, Loma Linda, CA
| |
Collapse
|
6
|
Santi MD, Zhang M, Salvo E, Asam K, Viet C, Xie T, Amit M, Aouizerat B, Ye Y. Schwann Cells Induce Phenotypic Changes in Oral Cancer Cells. Adv Biol (Weinh) 2022; 6:e2200187. [PMID: 35925609 PMCID: PMC9474679 DOI: 10.1002/adbi.202200187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 07/18/2022] [Indexed: 01/28/2023]
Abstract
Head and neck cancer (HNC) is the seventh most common cancer worldwide, the majority being oral squamous cell carcinoma. Despite advances in cancer diagnosis and treatment, the survival rate of patients with HNC remains stagnant. The cancer-nerve interaction has been recognized as an important driver of cancer progression. Schwann cells, a type of peripheral glia, have been implicated in promoting cancer cell growth, migration, dispersion, and invasion into the nerve in many cancers. Here, it is demonstrated that the presence of Schwann cells makes oral cancer cells more aggressive by promoting their proliferation, extracellular matrix breakdown, and altering cell metabolism. Furthermore, oral cancer cells became larger, more circular, with more projections and nuclei following co-culturing with Schwann cells. RNA-sequencing analysis in oral cancer cells following exposure to Schwann cells shows corresponding changes in genes involved in the hallmarks of cancer and cell metabolism; the enriched KEGG pathways are spliceosome, RNA transport, cell cycle, axon guidance, signaling pathways regulating pluripotency of stem cells, cAMP signaling, WNT signaling, proteoglycans in cancer and PI3K-Akt signaling. Taken together, these results suggest a significant role for Schwann cells in facilitating oral cancer progression, highlighting their potential as a target to treat oral cancer progression.
Collapse
Affiliation(s)
- Maria Daniela Santi
- Bluestone Center for Clinical Research, College of Dentistry, New York University
- Department of Oral Maxillofacial Surgery, College of Dentistry, New York University
| | - Morgan Zhang
- Bluestone Center for Clinical Research, College of Dentistry, New York University
- Department of Oral Maxillofacial Surgery, College of Dentistry, New York University
| | - Elizabeth Salvo
- Bluestone Center for Clinical Research, College of Dentistry, New York University
- Department of Oral Maxillofacial Surgery, College of Dentistry, New York University
| | - Kesava Asam
- Bluestone Center for Clinical Research, College of Dentistry, New York University
- Department of Oral Maxillofacial Surgery, College of Dentistry, New York University
| | - Chi Viet
- Loma Linda University School of Dentistry, Loma Linda, CA92350
| | - Tongxin Xie
- Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX77030
| | - Moran Amit
- Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX77030
| | - Bradley Aouizerat
- Bluestone Center for Clinical Research, College of Dentistry, New York University
- Department of Oral Maxillofacial Surgery, College of Dentistry, New York University
| | - Yi Ye
- Bluestone Center for Clinical Research, College of Dentistry, New York University
- Department of Oral Maxillofacial Surgery, College of Dentistry, New York University
| |
Collapse
|
7
|
Flowers E, Asam K, Allen IE, Kanaya AM, Aouizerat BE. Co‑expressed microRNAs, target genes and pathways related to metabolism, inflammation and endocrine function in individuals at risk for type 2 diabetes. Mol Med Rep 2022; 25:156. [PMID: 35244194 PMCID: PMC8941378 DOI: 10.3892/mmr.2022.12672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 02/03/2022] [Indexed: 11/25/2022] Open
Abstract
MicroRNAs (miRNAs) may be considered important regulators of risk for type 2 diabetes (T2D). The aim of the present study was to identify novel sets of miRNAs associated with T2D risk, as well as their gene and pathway targets. Circulating miRNAs (n=59) were measured in plasma from participants in a previously completed clinical trial (n=82). An agnostic statistical approach was applied to identify novel sets of miRNAs with optimal co-expression patterns. In silico analyses were used to identify the messenger RNA and biological pathway targets of the miRNAs within each factor. A total of three factors of miRNAs were identified, containing 18, seven and two miRNAs each. Eight biological pathways were revealed to contain genes targeted by the miRNAs in all three factors, 38 pathways contained genes targeted by the miRNAs in two factors, and 55, 18 and two pathways were targeted by the miRNAs in a single factor, respectively (all q<0.05). The pathways containing genes targeted by miRNAs in the largest factor shared a common theme of biological processes related to metabolism and inflammation. By contrast, the pathways containing genes targeted by miRNAs in the second largest factor were related to endocrine function and hormone activity. The present study focused on the pathways uniquely targeted by each factor of miRNAs in order to identify unique mechanisms that may be associated with a subset of individuals. Further exploration of the genes and pathways related to these biological themes may provide insights about the subtypes of T2D and lead to the identification of novel therapeutic targets.
Collapse
Affiliation(s)
- Elena Flowers
- Department of Physiological Nursing, University of California San Francisco, San Francisco, CA 94143‑0610, USA
| | - Kesava Asam
- Bluestone Center for Clinical Research, New York University, New York, NY 10010, USA
| | - Isabel Elaine Allen
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94143‑0610, USA
| | - Alka M Kanaya
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94143‑0610, USA
| | - Bradley E Aouizerat
- Bluestone Center for Clinical Research, New York University, New York, NY 10010, USA
| |
Collapse
|
8
|
Viet CT, Zhang X, Xu K, Yu G, Asam K, Thomas CM, Callahan NF, Doan C, Walker PC, Nguyen K, Kidd SC, Lee SC, Grandhi A, Allen CT, Young S, Melville JC, Shum JW, Viet DT, Herford AS, Roden DF, Gonzalez ML, Zhong JF, Aouizerat BE. Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer. Biomark Res 2021; 9:90. [PMID: 34930473 PMCID: PMC8686381 DOI: 10.1186/s40364-021-00349-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Accepted: 10/28/2021] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Oral squamous cell carcinoma (OSCC) has poor survival rates. There is a pressing need to develop more precise risk assessment methods to tailor clinical treatment. Epigenome-wide association studies in OSCC have not produced a viable biomarker. These studies have relied on methylation array platforms, which are limited in their ability to profile the methylome. In this study, we use MethylCap-Seq (MC-Seq), a comprehensive methylation quantification technique, and brush swab samples, to develop a noninvasive, readily translatable approach to profile the methylome in OSCC patients. METHODS Three OSCC patients underwent collection of cancer and contralateral normal tissue and brush swab biopsies, totaling 4 samples for each patient. Epigenome-wide DNA methylation quantification was performed using the SureSelectXT Methyl-Seq platform. DNA quality and methylation site resolution were compared between brush swab and tissue samples. Correlation and methylation value difference were determined for brush swabs vs. tissues for each respective patient and site (i.e., cancer or normal). Correlations were calculated between cancer and normal tissues and brush swab samples for each patient to determine the robustness of DNA methylation marks using brush swabs in clinical biomarker studies. RESULTS There were no significant differences in DNA yield between tissue and brush swab samples. Mapping efficiency exceeded 90% across all samples, with no differences between tissue and brush swabs. The average number of CpG sites with at least 10x depth of coverage was 2,716,674 for brush swabs and 2,903,261 for tissues. Matched tissue and brush swabs had excellent correlation (r = 0.913 for cancer samples and r = 0.951 for normal samples). The methylation profile of the top 1000 CpGs was significantly different between cancer and normal samples (mean p-value = 0.00021) but not different between tissues and brush swabs (mean p-value = 0.11). CONCLUSIONS Our results demonstrate that MC-Seq is an efficient platform for epigenome profiling in cancer biomarker studies, with broader methylome coverage than array-based platforms. Brush swab biopsy provides adequate DNA yield for MC-Seq, and taken together, our findings set the stage for development of a non-invasive methylome quantification technique for oral cancer with high translational potential.
Collapse
Affiliation(s)
- Chi T Viet
- Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, Loma Linda, CA, USA.
| | - Xinyu Zhang
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
- VA Connecticut Healthcare System, West Haven, CT, USA
| | - Ke Xu
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
- VA Connecticut Healthcare System, West Haven, CT, USA
| | - Gary Yu
- New York University Rory Meyers College of Nursing, New York, NY, USA
| | - Kesava Asam
- Department of Oral and Maxillofacial Surgery, New York University College of Dentistry, New York, NY, USA
- Bluestone Center for Clinical Research, New York University College of Dentistry, New York, NY, USA
| | - Carissa M Thomas
- Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Nicholas F Callahan
- Department of Oral and Maxillofacial Surgery, University of Illinois Chicago, College of Dentistry, Chicago, IL, USA
| | - Coleen Doan
- Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, Loma Linda, CA, USA
| | - Paul C Walker
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Khanh Nguyen
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Stephanie C Kidd
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Steve C Lee
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Anupama Grandhi
- Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, Loma Linda, CA, USA
| | - Clint T Allen
- Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Simon Young
- Department of Oral, Head and Neck Oncology and Microvascular Reconstructive Surgery, School of Dentistry, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - James C Melville
- Department of Oral, Head and Neck Oncology and Microvascular Reconstructive Surgery, School of Dentistry, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Jonathan W Shum
- Department of Oral, Head and Neck Oncology and Microvascular Reconstructive Surgery, School of Dentistry, University of Texas Health Science Center at Houston, Houston, TX, USA
| | | | - Alan S Herford
- Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, Loma Linda, CA, USA
| | - Dylan F Roden
- Department of Otolaryngology, Rutgers New Jersey Medical School, Newark, NJ, USA
| | - Manuel L Gonzalez
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Jiang F Zhong
- Department of Basic Sciences, Loma Linda University, School of Medicine, Loma Linda, CA, USA
| | - Bradley E Aouizerat
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
- VA Connecticut Healthcare System, West Haven, CT, USA
- New York University Rory Meyers College of Nursing, New York, NY, USA
| |
Collapse
|
9
|
Dasgupta K, Cesario JM, Ha S, Asam K, Deacon LJ, Song AH, Kim J, Cobb J, Yoon JK, Jeong J. R-Spondin 3 Regulates Mammalian Dental and Craniofacial Development. J Dev Biol 2021; 9:jdb9030031. [PMID: 34449628 PMCID: PMC8395884 DOI: 10.3390/jdb9030031] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Revised: 08/06/2021] [Accepted: 08/07/2021] [Indexed: 12/14/2022] Open
Abstract
Development of the teeth requires complex signaling interactions between the mesenchyme and the epithelium mediated by multiple pathways. For example, canonical WNT signaling is essential to many aspects of odontogenesis, and inhibiting this pathway blocks tooth development at an early stage. R-spondins (RSPOs) are secreted proteins, and they mostly augment WNT signaling. Although RSPOs have been shown to play important roles in the development of many organs, their role in tooth development is unclear. A previous study reported that mutating Rspo2 in mice led to supernumerary lower molars, while teeth forming at the normal positions showed no significant anomalies. Because multiple Rspo genes are expressed in the orofacial region, it is possible that the relatively mild phenotype of Rspo2 mutants is due to functional compensation by other RSPO proteins. We found that inactivating Rspo3 in the craniofacial mesenchyme caused the loss of lower incisors, which did not progress beyond the bud stage. A simultaneous deletion of Rspo2 and Rspo3 caused severe disruption of craniofacial development from early stages, which was accompanied with impaired development of all teeth. Together, these results indicate that Rspo3 is an important regulator of mammalian dental and craniofacial development.
Collapse
Affiliation(s)
- Krishnakali Dasgupta
- Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; (K.D.); (J.M.C.); (S.H.); (K.A.); (L.J.D.); (A.H.S.); (J.K.)
| | - Jeffry M. Cesario
- Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; (K.D.); (J.M.C.); (S.H.); (K.A.); (L.J.D.); (A.H.S.); (J.K.)
| | - Sara Ha
- Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; (K.D.); (J.M.C.); (S.H.); (K.A.); (L.J.D.); (A.H.S.); (J.K.)
| | - Kesava Asam
- Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; (K.D.); (J.M.C.); (S.H.); (K.A.); (L.J.D.); (A.H.S.); (J.K.)
| | - Lindsay J. Deacon
- Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; (K.D.); (J.M.C.); (S.H.); (K.A.); (L.J.D.); (A.H.S.); (J.K.)
| | - Ana H. Song
- Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; (K.D.); (J.M.C.); (S.H.); (K.A.); (L.J.D.); (A.H.S.); (J.K.)
| | - Julie Kim
- Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; (K.D.); (J.M.C.); (S.H.); (K.A.); (L.J.D.); (A.H.S.); (J.K.)
| | - John Cobb
- Department of Biological Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada;
| | - Jeong Kyo Yoon
- Soonchunhyang Institute of Medi-Bio Science, Soonchunhyang University, Cheonan 31151, Korea;
- Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan 31151, Korea
| | - Juhee Jeong
- Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; (K.D.); (J.M.C.); (S.H.); (K.A.); (L.J.D.); (A.H.S.); (J.K.)
- Correspondence:
| |
Collapse
|
10
|
Viet CT, Yu G, Asam K, Thomas CM, Yoon AJ, Wongworawat YC, Haghighiabyaneh M, Kilkuts CA, McGue CM, Couey MA, Callahan NF, Doan C, Walker PC, Nguyen K, Kidd SC, Lee SC, Grandhi A, Cheng AC, Patel AA, Philipone E, Ricks OL, Allen CT, Aouizerat BE. The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma. Biomark Res 2021; 9:42. [PMID: 34090518 PMCID: PMC8178935 DOI: 10.1186/s40364-021-00292-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 05/06/2021] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Oral squamous cell carcinoma (OSCC) is a capricious cancer with poor survival rates, even for early-stage patients. There is a pressing need to develop more precise risk assessment methods to appropriately tailor clinical treatment. Genome-wide association studies have not produced a viable biomarker. However, these studies are limited by using heterogeneous cohorts, not focusing on methylation although OSCC is a heavily epigenetically-regulated cancer, and not combining molecular data with clinicopathologic data for risk prediction. In this study we focused on early-stage (I/II) OSCC and created a risk score called the REASON score, which combines clinicopathologic characteristics with a 12-gene methylation signature, to predict the risk of 5-year mortality. METHODS We combined data from an internal cohort (n = 515) and The Cancer Genome Atlas (TCGA) cohort (n = 58). We collected clinicopathologic data from both cohorts to derive the non-molecular portion of the REASON score. We then analyzed the TCGA cohort DNA methylation data to derive the molecular portion of the risk score. RESULTS 5-year disease specific survival was 63% for the internal cohort and 86% for the TCGA cohort. The clinicopathologic features with the highest predictive ability among the two the cohorts were age, race, sex, tobacco use, alcohol use, histologic grade, stage, perineural invasion (PNI), lymphovascular invasion (LVI), and margin status. This panel of 10 non-molecular features predicted 5-year mortality risk with a concordance (c)-index = 0.67. Our molecular panel consisted of a 12-gene methylation signature (i.e., HORMAD2, MYLK, GPR133, SOX8, TRPA1, ABCA2, HGFAC, MCPH1, WDR86, CACNA1H, RNF216, CCNJL), which had the most significant differential methylation between patients who survived vs. died by 5 years. All 12 genes have already been linked to survival in other cancers. Of the genes, only SOX8 was previously associated with OSCC; our study was the first to link the remaining 11 genes to OSCC survival. The combined molecular and non-molecular panel formed the REASON score, which predicted risk of death with a c-index = 0.915. CONCLUSIONS The REASON score is a promising biomarker to predict risk of mortality in early-stage OSCC patients. Validation of the REASON score in a larger independent cohort is warranted.
Collapse
Affiliation(s)
- Chi T Viet
- Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, 11092 Anderson St., Suite 3304, Loma Linda, CA, 92350, USA.
| | - Gary Yu
- New York University Rory Meyers College of Nursing, New York, NY, USA
| | - Kesava Asam
- Department of Oral and Maxillofacial Surgery, New York University College of Dentistry, New York, NY, USA
- Bluestone Center for Clinical Research, New York University College of Dentistry, New York, NY, USA
| | - Carissa M Thomas
- Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Angela J Yoon
- Division of Oral and Maxillofacial Pathology, Department of Pathology & Cell Biology, Columbia University College of Dental Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Yan Chen Wongworawat
- Department of Pathology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Mina Haghighiabyaneh
- Department of Pathology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Courtney A Kilkuts
- Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, 11092 Anderson St., Suite 3304, Loma Linda, CA, 92350, USA
| | - Caitlyn M McGue
- Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, 11092 Anderson St., Suite 3304, Loma Linda, CA, 92350, USA
| | - Marcus A Couey
- Head and Neck Surgery, Providence Cancer Institute, Portland, OR, USA
- Head and Neck Surgery, Legacy Cancer Center, Portland, OR, USA
| | - Nicholas F Callahan
- Department of Oral and Maxillofacial Surgery, University of Illinois at Chicago, College of Dentistry, Chicago, IL, USA
| | - Coleen Doan
- Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, 11092 Anderson St., Suite 3304, Loma Linda, CA, 92350, USA
| | - Paul C Walker
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Khanh Nguyen
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Stephanie C Kidd
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Steve C Lee
- Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA, USA
| | - Anupama Grandhi
- Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, 11092 Anderson St., Suite 3304, Loma Linda, CA, 92350, USA
| | - Allen C Cheng
- Head and Neck Surgery, Providence Cancer Institute, Portland, OR, USA
- Head and Neck Surgery, Legacy Cancer Center, Portland, OR, USA
| | - Ashish A Patel
- Head and Neck Surgery, Providence Cancer Institute, Portland, OR, USA
- Head and Neck Surgery, Legacy Cancer Center, Portland, OR, USA
| | - Elizabeth Philipone
- Division of Oral and Maxillofacial Pathology, Department of Pathology & Cell Biology, Columbia University College of Dental Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Olivia L Ricks
- School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Clint T Allen
- Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Bradley E Aouizerat
- New York University Rory Meyers College of Nursing, New York, NY, USA
- Department of Oral and Maxillofacial Surgery, New York University College of Dentistry, New York, NY, USA
- Bluestone Center for Clinical Research, New York University College of Dentistry, New York, NY, USA
| |
Collapse
|
11
|
Dasgupta K, Chung JU, Asam K, Jeong J. Molecular patterning of the embryonic cranial mesenchyme revealed by genome-wide transcriptional profiling. Dev Biol 2019; 455:434-448. [PMID: 31351040 PMCID: PMC6842427 DOI: 10.1016/j.ydbio.2019.07.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Revised: 07/22/2019] [Accepted: 07/22/2019] [Indexed: 12/12/2022]
Abstract
In the head of an embryo, a layer of mesenchyme surrounds the brain underneath the surface ectoderm. This cranial mesenchyme gives rise to the meninges, the calvaria (top part of the skull), and the dermis of the scalp. Abnormal development of these structures, especially the meninges and the calvaria, is linked to significant congenital defects in humans. It has been known that different areas of the cranial mesenchyme have different fates. For example, the calvarial bone develops from the cranial mesenchyme on the baso-lateral side of the head just above the eye (supraorbital mesenchyme, SOM), but not from the mesenchyme apical to SOM (early migrating mesenchyme, EMM). However, the molecular basis of this difference is not fully understood. To answer this question, we compared the transcriptomes of EMM and SOM using high-throughput sequencing (RNA-seq). This experiment identified a large number of genes that were differentially expressed in EMM and SOM, and gene ontology analyses found very different terms enriched in each region. We verified the expression of about 40 genes in the head by RNA in situ hybridization, and the expression patterns were annotated to make a map of molecular markers for 6 subdivisions of the cranial mesenchyme. Our data also provided insights into potential novel regulators of cranial mesenchyme development, including several axon guidance pathways, lectin complement pathway, cyclic-adenosine monophosphate (cAMP) signaling pathway, and ZIC family transcription factors. Together, information in this paper will serve as a unique resource to guide future research on cranial mesenchyme development.
Collapse
Affiliation(s)
- Krishnakali Dasgupta
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, 10010, USA
| | - Jong Uk Chung
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, 10010, USA
| | - Kesava Asam
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, 10010, USA
| | - Juhee Jeong
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, 10010, USA.
| |
Collapse
|
12
|
Cesario JM, Landin Malt A, Chung JU, Khairallah MP, Dasgupta K, Asam K, Deacon LJ, Choi V, Almaidhan AA, Darwiche NA, Kim J, Johnson RL, Jeong J. Anti-osteogenic function of a LIM-homeodomain transcription factor LMX1B is essential to early patterning of the calvaria. Dev Biol 2018; 443:103-116. [PMID: 29852132 DOI: 10.1016/j.ydbio.2018.05.022] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 05/15/2018] [Accepted: 05/26/2018] [Indexed: 12/22/2022]
Abstract
The calvaria (upper part of the skull) is made of plates of bone and fibrous joints (sutures and fontanelles), and the proper balance and organization of these components are crucial to normal development of the calvaria. In a mouse embryo, the calvaria develops from a layer of head mesenchyme that surrounds the brain from shortly after mid-gestation. The mesenchyme just above the eye (supra-orbital mesenchyme, SOM) generates ossification centers for the bones, which then grow toward the apex gradually. In contrast, the mesenchyme apical to SOM (early migrating mesenchyme, EMM), including the area at the vertex, does not generate an ossification center. As a result, the dorsal midline of the head is occupied by sutures and fontanelles at birth. To date, the molecular basis for this regional difference in developmental programs is unknown. The current study provides vital insights into the genetic regulation of calvarial patterning. First, we showed that osteogenic signals were active in both EMM and SOM during normal development, which suggested the presence of an anti-osteogenic factor in EMM to counter the effect of these signals. Subsequently, we identified Lmx1b as an anti-osteogenic gene that was expressed in EMM but not in SOM. Furthermore, head mesenchyme-specific deletion of Lmx1b resulted in heterotopic ossification from EMM at the vertex, and craniosynostosis affecting multiple sutures. Conversely, forced expression of Lmx1b in SOM was sufficient to inhibit osteogenic specification. Therefore, we conclude that Lmx1b plays a key role as an anti-osteogenic factor in patterning the head mesenchyme into areas with different osteogenic competence. In turn, this patterning event is crucial to generating the proper organization of the bones and soft tissue joints of the calvaria.
Collapse
Affiliation(s)
- Jeffry M Cesario
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - André Landin Malt
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - Jong Uk Chung
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - Michael P Khairallah
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - Krishnakali Dasgupta
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - Kesava Asam
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - Lindsay J Deacon
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - Veronica Choi
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - Asma A Almaidhan
- Department of Orthodontics, New York University College of Dentistry, New York, NY, United States
| | - Nadine A Darwiche
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - Jimin Kim
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States
| | - Randy L Johnson
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Juhee Jeong
- Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, United States.
| |
Collapse
|
13
|
Asam K, Staniszewski A, Zhang H, Melideo SL, Mazzeo A, Voronkov M, Huber KL, Pérez E, Stock M, Stock JB, Arancio O, Nicholls RE. Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid. PLoS One 2017; 12:e0189413. [PMID: 29253878 PMCID: PMC5734769 DOI: 10.1371/journal.pone.0189413] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Accepted: 11/24/2017] [Indexed: 02/04/2023] Open
Abstract
Soluble forms of oligomeric beta-amyloid (Aβ) are thought to play a central role in Alzheimer's disease (AD). Transgenic manipulation of methylation of the serine/threonine protein phosphatase, PP2A, was recently shown to alter the sensitivity of mice to AD-related impairments resulting from acute exposure to elevated levels of Aβ. In addition, eicosanoyl-5-hydroxytryptamide (EHT), a naturally occurring component from coffee beans that modulates PP2A methylation, was shown to confer therapeutic benefits in rodent models of AD and Parkinson's disease. Here, we tested the hypothesis that EHT protects animals from the pathological effects of exposure to elevated levels of soluble oligomeric Aβ. We treated mice with EHT-containing food at two different doses and assessed the sensitivity of these animals to Aβ-induced behavioral and electrophysiological impairments. We found that EHT administration protected animals from Aβ-induced cognitive impairments in both a radial-arm water maze and contextual fear conditioning task. We also found that both chronic and acute EHT administration prevented Aβ-induced impairments in long-term potentiation. These data add to the accumulating evidence suggesting that interventions with pharmacological agents, such as EHT, that target PP2A activity may be therapeutically beneficial for AD and other neurological conditions.
Collapse
Affiliation(s)
- Kesava Asam
- Department of Pathology and Cell Biology, Columbia University, New York, NY, United States of America
- The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, United States of America
| | - Agnieszka Staniszewski
- Department of Pathology and Cell Biology, Columbia University, New York, NY, United States of America
- The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, United States of America
| | - Hong Zhang
- Department of Pathology and Cell Biology, Columbia University, New York, NY, United States of America
- The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, United States of America
| | - Scott L. Melideo
- Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America
| | - Adolfo Mazzeo
- Department of Pathology and Cell Biology, Columbia University, New York, NY, United States of America
- The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, United States of America
| | - Michael Voronkov
- Signum Biosciences, 133 Wall Street, Princeton, New Jersey, United States of America
| | - Kristen L. Huber
- Signum Biosciences, 133 Wall Street, Princeton, New Jersey, United States of America
| | - Eduardo Pérez
- Signum Biosciences, 133 Wall Street, Princeton, New Jersey, United States of America
| | - Maxwell Stock
- Signum Biosciences, 133 Wall Street, Princeton, New Jersey, United States of America
| | - Jeffry B. Stock
- Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America
- Signum Biosciences, 133 Wall Street, Princeton, New Jersey, United States of America
| | - Ottavio Arancio
- Department of Pathology and Cell Biology, Columbia University, New York, NY, United States of America
- The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, United States of America
- Department of Medicine, Columbia University, New York, NY, United States of America
| | - Russell E. Nicholls
- Department of Pathology and Cell Biology, Columbia University, New York, NY, United States of America
- The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, United States of America
- * E-mail:
| |
Collapse
|